The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and onset of the coronavirus disease-19 (COVID-19) pandemic led to an immediate need for therapeutic treatment options. Therapeutic antibodies were developed to fill a gap when traditional antivirals were not available. In late 2020, the United States Government undertook an effort to compare candidate therapeutic antibodies in virus neutralization assays and in the hamster model of SARS-CoV-2 infection. With the emergence of SARS-CoV-2 variants, the effort expanded to evaluate the efficacy of nearly 50 products against major variants. A subset of products was further evaluated for therapeutic efficacy in hamsters. Here we report results of the hamster studies, including pathogenicity with multiple variants, neutralization capacity of products, and efficacy testing of products against Delta and Omicron variants. These studies demonstrate the loss of efficacy of early products with variant emergence and support the use of the hamster model for evaluating therapeutics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421207 | PMC |
| http://dx.doi.org/10.1016/j.antiviral.2024.105987 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.
Neuropharmacology
January 2025
Department of Neuroscience, University of Minnesota, Minneapolis, MN 55455 USA.
Hypoactive sexual desire disorder (HSDD) is the most reported sexual dysfunction among premenopausal women worldwide. Bremelanotide, trade name Vyleesi, has been approved by the United States Food and Drug Administration to treat HSDD. However, despite approval, very little is known about its neurobiological mechanism of action.
View Article and Find Full Text PDFPreclinical evaluation of the potential PARP-imaging probe [carbonyl-C]DPQ.
EJNMMI Radiopharm Chem
January 2025
Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Background: Poly (ADP-ribose) polymerase (PARP) enzymes are crucial for the repair of DNA single-strand breaks and have become key therapeutic targets in homologous recombination-deficient cancers, including prostate cancer. To enable non-invasive monitoring of PARP-1 expression, several PARP-1-targeting positron emission tomography (PET) tracers have been developed. Here, we aimed to preclinically investigate [carbonyl-C]DPQ as an alternative PARP-1 PET tracer as it features a strongly distinct chemotype compared to the frontrunners [F]FluorThanatrace and [F]PARPi.
View Article and Find Full Text PDFA bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection.
NPJ Vaccines
January 2025
Providence Therapeutics Holdings, Inc., Calgary, Canada.
Continuously emerging SARS-CoV-2 Omicron subvariants pose a threat thwarting the effectiveness of approved COVID-19 vaccines. Especially, the protection breadth and degree of these vaccines against antigenically distant Omicron subvariants is unclear. Here, we report the immunogenicity and efficacy of a bivalent mRNA vaccine, PTX-COVID19-M1.
View Article and Find Full Text PDFChallenges in establishing small animal models for : Host specificity and resistance to infection in rodent hosts.
MicroPubl Biol
December 2024
Microbiology, Immunology, and Tropical Medicine, George Washington University, Washington, Washington, D.C., United States.
This study explores potential small animal models for the dog hookworm, , a parasitic nematode which has repeatedly exhibited the ability to develop resistance to a range of anthelmintics. Immunomodulated hamsters, gerbils, rats, and mice were infected with Despite varying degrees of immunosuppression, and in some cases, total adaptive immunodeficiency, no adult worms were recovered, and larval arrest (L3 stage) occurred in muscle tissue of mice and hamsters. This highlights the strict host specificity of and emphasizes the challenges of developing rodent models usable for anthelmintic testing with a strict specialist parasite.
View Article and Find Full Text PDFPersistent Rhesus Enteric Calicivirus Infection in Recombinant CHO Cells Expressing the Coxsackie and Adenovirus Receptor.
Viruses
November 2024
Department of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, TX 77843, USA.
Recently, using a panel of recombinant CHO cell lines, we identified the coxsackie and adenovirus receptor (CAR) and histo-blood group antigens (HBGAs) or sialic acid as the minimum requirement for susceptibility to rhesus enteric calicivirus (ReCV) infections. While ReCVs cause lytic infection in LLC-MK2 cells, recombinant CHO (rCHO) cell lines did not exhibit any morphological changes upon infection. To monitor infectious virus production, rCHO cell cultures had to be freeze-thawed and titrated on LLC-MK2 monolayers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!